机构：[1]LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA[2]Department of Hematology, West China Hospital, Sichuan University, Chengdu, China[3]UCD School of Medicine, College of Health and Agricultural Science and UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin, UCD, Dublin 4, Ireland and[4]State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Tianjin, China
National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1CA050947, RO1CA207237, P50CA100707]; Research Development Fund for Hematological Neoplasm from Chinese Anti-Cancer Association [312160342]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81302148]
语种：
外文
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2017]版：
大类|2 区医学
小类|2 区肿瘤学
最新[2023]版：
大类|1 区医学
小类|1 区血液学1 区肿瘤学
第一作者：
第一作者机构：[1]LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA[2]Department of Hematology, West China Hospital, Sichuan University, Chengdu, China
推荐引用方式(GB/T 7714)：
Zhang L,Tai Y-T,Ho M,et al.Regulatory B cell-myeloma cell interaction confers immunosuppression and promotes their survival in the bone marrow milieu.[J].Blood cancer journal.2017,7(3):e547.doi:10.1038/bcj.2017.24.
APA：
Zhang L,Tai Y-T,Ho M,Xing L,Chauhan D...&Anderson K C.(2017).Regulatory B cell-myeloma cell interaction confers immunosuppression and promotes their survival in the bone marrow milieu..Blood cancer journal,7,(3)
MLA：
Zhang L,et al."Regulatory B cell-myeloma cell interaction confers immunosuppression and promotes their survival in the bone marrow milieu.".Blood cancer journal 7..3(2017):e547
医学